21 Invest’s Post

From bench to bedside: Drug-Coated Balloons. “We were instrumental in launching the world’s first approved Drug-Coated Balloon device 15 years ago, and we have played a key role in the latest round of DCB launches,” shares Júlia Lleixà Calvet, PhD, Director of Business Development at Freudenberg Medical and Hemoteq AG in a recent DeviceTalks AbbottTalks podcast with Kayleen Brown. Building on this strong legacy and expertise, Julia shares her vision for the future—specifically improving outcomes for CLTI patients—and how Freudenberg Medical, alongside Hemoteq AG, will continue to support their expanding customer base on this journey. #DeviceTalks #InnovatingTogether #Medtech #DrugCoatedBalloons

We are thrilled to announce that Paragon 28 has entered into a definitive agreement to join forces with Zimmer Biomet, a global leader in medical technology. This milestone marks an incredible opportunity to expand our mission of delivering innovative solutions for the foot and ankle segment.   Please refer to the full press release for key information and cautionary statements: Full Press Release Here! https://lnkd.in/gkSFNdsJ   #paragon28 #P28 #footandankle #FNA #improvingpatientlives #dedicatedtofootandankle #zimmerbiomet #acquisition

From bench to bedside: Drug-Coated Balloons. “We were instrumental in launching the world’s first approved Drug-Coated Balloon device 15 years ago, and we have played a key role in the latest round of DCB launches,” shares Júlia Lleixà Calvet, PhD, Director of Business Development at Freudenberg Medical and Hemoteq AG in a recent DeviceTalks AbbottTalks podcast with Kayleen Brown. Building on this strong legacy and expertise, Julia shares her vision for the future—specifically improving outcomes for CLTI patients—and how Freudenberg Medical, alongside Hemoteq AG, will continue to support their expanding customer base on this journey. #DeviceTalks #innovatingtogether #Medtech #drugcoatedballoons 

NAMSA Acquires Medical Device Testing Ops of WuXi AppTec 👏 NAMSA has signed an agreement to acquire WuXi AppTec’s U.S. medical device testing operations in Minnesota and Georgia. This acquisition expands NAMSA’s capabilities in MedTech testing and clinical research, further solidifying its position as a leader in the industry. The move will enhance NAMSA’s ability to support MedTech innovators in navigating complex regulatory landscapes and accelerating time to market. This is NAMSA’s ninth acquisition since joining ARCHIMED in 2020. ➡️https://lnkd.in/eDQafrfn

Israeli start-up Magenta Medical Ltd., led by David Israeli, MD, is making headway toward becoming a disruptive player in the percutaneous left ventricular assist device (pLVAD) market. Today, that market is all but dominated by Abiomed’s (acquired by Johnson & Johnson in a $16.6 billion deal) Impella CP device, but Israeli has reason to believe that Magenta’s Elevate may be able to tip the scales with evidence of strong safety and performance profiles. Read more about how Magenta is the first company in some time to successfully complete a feasibility study in the US, despite ample competition: https://bit.ly/45Y9S3U #medtech #medicaldevices #medtechinnovation

BioWorld ’s Shani Alexander spoke with Antoine Papiernik, Sofinnova Partners’ Chairman and Managing Partner, on why this is such a promising time for the #medtech sector. Antoine discussed what it takes to build a successful medtech company, offering recent examples, such as Shockwave Medical, LimFlow SA, Pi-Cardia, HighLife, Moon Surgical and RefleXion Medical. He also highlighted what it takes to attract investor interest, demonstrating that the technology can transform a specific indication and significantly impact patients. Finally, bringing a product to market and achieving a successful exit takes time—Shockwave Medical, for example, took 12 years to become a billion-dollar company. 🔗Learn more: https://lnkd.in/eCpZJ-Ep

“We are delighted to have guided LAUXERA CAPITAL PARTNERS through this significant transaction, securing long-term capital for Acandis and positioning it for continued growth and innovation in the neurovascular medical device market”, states Corporate/M&A partner Romain Sabatier. 👉 Read the article: lnkd.in/eWZFdV-G. Romain Sabatier - Jean-Marc GROELLY - Hédi Khedache-Thiriet - Isabelle Absalon #mergerandacquisitions #neurovascular

Sanara MedTech, a Texas-based medtech firm has acquired a minority investment in Biomimetic Innovations Ltd (BMI), a Shannon-headquartered company that is seeking to commercialise its flagship bone adhesive solution, which is known as OsStic. BMI is currently led by Paul Burke, who also leads its affiliate, PBC Biomed

hVIVO PLC (AIM:HVO) chief executive Yamin (Mo) Khan speaks with Proactive's Stephen Gunnion about the company's achievements in the first half of 2024, including a 31% increase in revenue, reaching £35.6 million. Khan highlighted the company's record EBITDA of £8.7 million, reflecting a 68% year-on-year growth. He attributed these successes to the opening of the world’s largest human challenge trial facility in Canary Wharf, which includes 50 beds for CL3 level pathogen trials. Khan also spoke about hVIVO’s strategic expansion of service offerings beyond human challenge trials, including laboratory services and patient recruitment via its FluCamp platform. He emphasised the company’s strong order book, valued at £71 million, and its sales pipeline, which includes £40 million worth of opportunities. As hVIVO looks ahead, Khan reiterated the company’s guidance for 2024 revenue of £62 million and an EBITDA margin at the... Watch at #Proactive #ProactiveInvestors http://ow.ly/1Xze105IcW7

#HotOffThePress #MergerAndAcquisitions #TrendingInMedTech #PointOfView Stryker's announcement to acquire Inari Medical for $4.9 billion represents a significant strategic move, particularly strengthening Stryker's position in the #peripheralvascular segment. This acquisition enables Stryker to expand its portfolio with Inari's innovative #venousthromboembolism (VTE) treatments, which complement its existing #neurovascular business. For Stryker, this deal not only broadens its product offerings but also accelerates its impact in #endovascular procedures, potentially elevating the standard of care for VTE patients. Additionally, Inari's strong revenue growth trajectory, with expected revenues of $603 million in 2024 (up from $494 million in 2023 and $383 million in 2022), highlights the financial benefits of this acquisition. For the MedTech industry, this acquisition underscores the ongoing trend of consolidation and the importance of innovative solutions in addressing unmet patient needs. The deal also reflects Stryker's commitment to leveraging its global infrastructure to enhance patient care and drive further innovation.